Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortés, David W. Cescon, Hope S. Rugo et al.|The Lancet|2020Cited by 1.8kOpen Access
SC21.02 IMAS: A TOTAL BODY PET WITH TOF AND DOI CAPABILITIESA.J. Gonzalez Martinez, Sánchez David, Jiménez-Serrano Santiago et al.|Physica Medica|2024Cited by 0